Aimmune's peanut allergy therapy meets in Phase III

Aimmune Therapeutics Inc. (NASDAQ:AIMT) said AR101 met the primary endpoint in the Phase III PALISADE trial to treat peanut allergy, but also reported that a greater proportion of patients in the active arm discontinued treatment compared to placebo. The news drove Aimmune shares down $2.24 to $34.96 on Tuesday.

Aimmune plans to submit a BLA to FDA by year end and an MAA to EMA in 1H19...